BETHESDA, MD. — A fully “closed-loop” insulin pump delivery system is still several steps away, but steady progress is being made toward the creation of a functional artificial pancreas that provides far better glucose control for type 1 diabetic patients than is currently available.
That was the consensus from a meeting sponsored by the National Institutes of Health and the Juvenile Diabetes Research Foundation in which scientists, clinicians, and industry representatives came together to address the current state of the art and to discuss ways of overcoming technical obstacles.
Over the last 2 decades, external insulin pump therapy has become a standard treatment option for patients with type 1 diabetes. Current pumps are “open loop,” meaning that they require input from the user, both in setting the background (basal) infusion rate and for delivering premeal boluses based on the blood glucose level and anticipated carbohydrate consumption. Recent advances have incorporated a continuous glucose monitor into the system along with algorithms that estimate the bolus dose, but the technology still requires user input—and therefore is subject to some degree of error.
The main problem isn't in delivering the insulin. Rather, it's overcoming the numerous technical barriers to developing a real-time sensor that can respond to the current glucose level, as well as its rate and direction of change. Moreover, algorithms linking the sensor with the delivery system must also account for all the other physiologic factors that contribute to glucose homeostasis, such as incretins, free fatty acids, and counterregulatory hormones.
“There are three elements to a closed-loop system: the delivery device, the sensing device, and linking algorithms. Each element is very complex, and difficult to develop. Each must really be developed independently before you can put together a complete closed-loop system,” explained Dr. Christopher D. Saudek, professor of medicine at the Johns Hopkins University and director of the Johns Hopkins Diabetes Center, Baltimore.
But Dr. Saudek, who has been researching open-loop implantable pumps for the last 25 years, still sees mechanical insulin delivery as more immediately promising than a biological approach such as islet or stem cell transplantation. “Either would be a cure if it worked reliably and well. But the biological approach still requires enormous basic science breakthroughs before it will help people. The mechanical approach is applied research. It's a matter of refining techniques we have that work.”
The preference for mechanical “cure” certainly applies to children and adolescents, for whom the need for lifelong immune suppression following transplantation is undesirable, said Dr. William V. Tamborlane, professor of pediatrics and chief of pediatric endocrinology at Yale University, New Haven, Conn.
Maintaining good diabetes control is particularly difficult in adolescents, and not just because they tend to be rebellious and noncompliant. Teenagers experience wide swings in glucose because their unique physiology makes them more insulin resistant while paradoxically more vulnerable to hypoglycemia, especially at night. “The development of a closed-loop artificial pancreas is the most likely candidate to revolutionize the treatment of childhood type 1 diabetes in the foreseeable future,” Dr. Tamborlane said.
He reviewed preliminary results of short-term (30–35 hours), closed-loop control in seven adolescents with type 1 diabetes, using Medtronic Minimed's external glucose sensor and infusion pump (information about both available at www.minimed.com
However, despite multiple premeal infusion adjustments, peak postmeal blood glucose levels often exceeded 200 mg/dL, particularly after breakfast.
Currently under investigation is “semi-automatic” or “hybrid” strategy, where the patient manually administers a partial, priming dose of insulin prior to eating, with the remaining insulin regulated by the system. Although not closed loop, this would be a great improvement over currently available technology, Dr. Tamborlane noted.
The same would be true of an imperfect completely closed loop: “Now, when my patients forget to bolus, their blood glucose goes up to 400 [mg/dL]. At least with a closed loop, it would only go to 250. … Maybe we don't need to aim for perfect,” he said.
Similar postmeal problems were seen among 22 young adults with type 1 diabetes in whom a system developed by Roche Diagnostics (www.roche-diagnostics.com
This system utilized an empirical glucose-control algorithm based on a calculation of the current glucose concentration and its gradient, the remaining effect of already-infused insulin, the amount of carbohydrate intake, and patient-specific factors such as basal insulin requirement and insulin-to-carbohydrate ratio. As with the adolescents, overnight values approached the target of 120 mg/dL, with only half the variability that occurred among the patients without the controller. But blood glucose values remained highly variable throughout meal times, again particularly after breakfast.